Status:
COMPLETED
To Assess the Accuracy of the eZscan Study in the Screening for Diabetic Nephropathy
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
21-75 years
Brief Summary
Diabetes mellitus (DM) is a metabolic disorder commonly encountered by the healthcare professionals. Diabetic nephropathy is one of its complications, which is becoming the most common cause of end-st...
Detailed Description
Patients with type 2 diabetes mellitus with and without diabetic nephropathy will be identified from clinical records and approached for their interest in participating in the study. Written informed ...
Eligibility Criteria
Inclusion
- Male or female aged between 21 and 75 years (inclusive).
- Has confirmed type 2 diabetes mellitus
- With or without diabetic nephropathy based on recent complication screening
- Written informed consent given
Exclusion
- Has amputation of arm or leg
- Uses beta blockers or drugs known to affect the sympathetic nervous system
- Has an electrical implantable device (pacemaker, defibrillator)
- Known to have sensitivity to nickel or any other standard electrodes
- Sufferers from epilepsy or seizures
- Patients on renal replacement therapy
- Patients with chronic kidney disease due to known non-diabetes causes e.g. renal stone or obstructive uropathy.
- Patients confirmed to have urinary tract infection on the day of assessment.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01163591
Start Date
January 1 2009
End Date
October 1 2009
Last Update
October 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diabetes Mellitus and Endocrine Centre, Prince of Wales Hospital
Shatin, Hong Kong, China